Previously, the cumulative incidence of disease progression to myelodysplastic syndrome and/or AML was reported to be 13% after 8 years of G‐CSF treatment and up to 22% and 31% after 15 years of G‐CSF treatment, according to data from the Severe Chronic Neutropenia International Registry [30]. This evidence concerns the gene CSF3 and acute myeloid leukemia.